Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yttrium Y 90 anti-CEA monoclonal antibody cT84.66
- Development stage
- Phase 2
- Lead developer
- City of Hope National Medical Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A radioimmunoconjugate comprised of a chimeric monoclonal antibody (cT84.66) directed against human carcinoembryonic antigen (CEA), conjugated to the beta-emitting radioisotope yttrium-90 via the chelator DOTA (tetra-azacyclododecanetetra-acetic acid). The antibody moiety binds specifically to CEA-expressing tumor cells; upon internalization, it delivers cytotoxic beta radiation directly to these cells, resulting in targeted cell death while sparing most normal tissues[1][7][8]. CEA is overexpressed in many cancers including gastrointestinal, breast, non-small cell lung cancer (NSCLC), and thyroid cancers[7][8]. This agent has been investigated primarily for use in patients with metastatic or unresectable CEA-positive malignancies as a form of targeted radiotherapy[1][2][4].
- Other names
- yttrium Y 90 DOTA anti-CEA monoclonal antibody cT84.6690Y-DOTA-cT84.66radioimmunoconjugate of chimeric T84.66 anti-CEA mAb with yttrium-90
Beyond the preview
Go deeper on yttrium Y 90 anti-CEA monoclonal antibody cT84.66.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yttrium Y 90 anti-CEA monoclonal antibody cT84.66.